TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01023373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: hypotensive drugs, statins and anti-platelets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTRS
Description: Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal artery stent
Description: Non-drug intervention, percutaneous transluminal renal artery stent angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renal artery stent
Description: Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal artery stent
Description: Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
Study: NCT01816373

Intervention type: DEVICE
Group type: OTHER
Intervention: Vacuum Bell
Description: Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
Study: NCT01235507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
Study: NCT01681290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX129801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX129801
Study: NCT01977157

Intervention type: DEVICE
Intervention: bioimpedance mesurements
Description: Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
Study: NCT01968304

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Iron status follow up
Study: NCT01386229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
Study: NCT01502761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intra-arterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intra-arterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intra-arterial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intra-arterial
Study: NCT01905904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevorane
Description: Sevorane 4% Sevorane 7%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevorane
Description: Sevorane 4% Sevorane 7%
Study: NCT00725829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Simvastatin 40mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin
Description: Simvastatin 40mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00948285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: magnetic resonance imaging (MRI)
Study: NCT04551560

Intervention type: OTHER
Group type: OTHER
Intervention: Mental Stress
Description: Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
Study: NCT00373880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole + Cocaine
Description: Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cocaine
Description: Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
Study: NCT03928444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intradermal injection of adipose derived stem cells to one side of the face
Description: Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intradermal injection of saline to one side of the face
Description: intradermal injection of saline to one side of the face
Study: NCT01611662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical cystectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04007367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo capsule
Study: NCT00702936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TELMISARTAN
Description: 80 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAMIPRIL
Description: 5 mg daily
Study: NCT03795636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garlic extract
Description: A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl (COLTENE®)
Description: Sodium hypochlorite
Study: NCT01764022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
Study: NCT00626340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDD diagnosis and Estrogen treatment
Description: Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDD diagnosis and Fluoxetine treatment
Description: Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDD diagnosis with both Estrogen and Fluoxetine treatment
Description: Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No depression and estrogen treatment
Description: Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
Study: NCT05355324

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02740894

Intervention type: DRUG
Intervention: Gefitinib

Intervention type: DRUG
Intervention: Gefitinib
Study: NCT03930927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self Assembling peptide
Description: enamel regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self Assembling peptide
Description: enamel regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remineralizing agent
Description: enamel regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remineralizing agent
Description: enamel regeneration
Study: NCT01466062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palivizumab
Study: NCT03531710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-311
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-311
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection
Study: NCT06446895

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronariography
Description: Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronariography
Description: Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
Study: NCT00865202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation
Description: L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-tryptophan supplementation
Description: L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
Study: NCT05580237

Intervention type: PROCEDURE
Intervention: Simultaneous right and left heart catheterization
Description: Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
Study: NCT06323499

Intervention type: PROCEDURE
Intervention: Induction of atypical atrial flutter
Description: Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
Study: NCT03077789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRABECULOTOMY
Description: Evaluation of the prognosis of different surgery in congenital glaucoma
Study: NCT00183261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef
Description: 1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MRKAd5 HIV-1 gag/pol/nef placebo
Description: 1.0 mL administered intramuscularly
Study: NCT03297944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2mg (2ALP/PLC)
Description: 2mg alprazolam administered at night, placebo administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 1mg (1ALP/PLC)
Description: 1mg alprazolam administered at night, placebo administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg (0.5ALP/PLC)
Description: 0.5mg alprazolam administered at night, placebo administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg (ZOL/PLC)
Description: 10mg alprazolam administered at night, placebo administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PLC/PLC)
Description: Placebo administered at night, placebo administered in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 1mg (PLC/ALC)
Description: Placebo administered at night, 1mg alprazolam administered in the morning.
Study: NCT03278444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic drugs therapy of HCC
Description: Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine hydrochloride
Description: Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
Study: NCT03378232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High EPA Supplement
Description: Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High DHA Supplement
Description: Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
Study: NCT03491371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylsulfonic apatinib
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylsulfonic apatinib
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylsulfonic apatinib
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylsulfonic apatinib
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
Study: NCT03634228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03052699

Intervention type: PROCEDURE
Intervention: vaginal Cesarean Section
Description: follow-up to patients operated for vaginal Cesarean Section
Study: NCT03794011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetoscopy
Description: The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
Study: NCT03658967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymfactin® (1x10E11 vp)
Description: Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
Study: NCT03049085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
Study: NCT00485329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain
Description: 15,000 USP U/ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain
Description: 30,000 USP U/ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain
Description: 60,000 USP U/ml
Study: NCT01467375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
Study: NCT01039155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03049085

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin C
Description: preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
Study: NCT03005119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTL201
Description: Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo seamless gelatin matrix green beads containing excipients only
Study: NCT02147717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser stimulation
Description: Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fake laser stimulation
Description: newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
Study: NCT01910896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight Intensive Patch
Description: Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
Study: NCT03190603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
Study: NCT02378779

Intervention type: OTHER
Group type: OTHER
Intervention: Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)
Description: The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
Study: NCT00217594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)